(Q43742716)

26 November 2017

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials (English)

1 reference

26 November 2017

C J Hawkey

1

1 reference

26 November 2017

L Laine

2

1 reference

26 November 2017

S E Harper

3

1 reference

26 November 2017

H U Quan

4

1 reference

26 November 2017

J A Bolognese

5

1 reference

26 November 2017

E Mortensen

6

1 reference

26 November 2017

Rofecoxib Osteoarthritis Endoscopy Multinational Study Group

7

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Alimentary Pharmacology & Therapeutics

26 November 2017

1 reference

26 November 2017

15

1 reference

26 November 2017

10

1 reference

26 November 2017

1593-1601

1 reference

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

26 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01007.X

10.1046/J.1365-2036.2001.01007.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference